TaiRx, Inc. (6580.TWO) Stock
TaiRx, Inc. focuses on the development and commercialization of therapeutics for the treatment of cancer and other diseases.
Valuation
Financials & Margins
Valuation & Return Ratios
About TaiRx, Inc.
TaiRx, Inc. focuses on the development and commercialization of therapeutics for the treatment of cancer and other diseases. The company's products under development include CVM-1118, an oral anti-cancer drug that is Phase II clinical trial. Its pre-clinical products comprise TRX-920, an oral delivery formulation; and TRX-105, a molecule developed for treating and alleviating symptoms of various colitis. The company also offers Zelnite, a drug that helps in treatment of selenium deficiency; and focuses on development of the nodal diagnostic devices and anti-body drugs for the use in cancer therapy. TaiRx, Inc. was founded in 2011 and is based in Taipei, Taiwan.
TaiRx, Inc. is led by CEO Du-Shieng Chien, employs 29 people, headquartered in Taipei City, TW, publicly traded since 2017.
TaiRx, Inc. (6580.TWO) stock trades at $12.80 with a market capitalization of $1.44B. The stock is valued at a negative price-to-earnings (P/E) ratio of -6.31, reflecting a net loss over the last twelve months, price-to-book of 3.92, price-to-sales of 48.74. Over the past 52 weeks the stock has ranged between $11.95 and $24.75, and currently trades 48.3% below its 52-week high.
On profitability, TaiRx, Inc. generates a return on equity (ROE) of -49.47% (negative, reflecting a net loss), an operating margin of -965.87%.
Official website: www.trx.com.tw
TaiRx, Inc. (6580.TWO) — frequently asked questions
What is TaiRx, Inc. (6580.TWO) stock price today?
TaiRx, Inc. (6580.TWO) is currently trading at $12.80, down 3.03% today.
What is 6580.TWO P/E ratio?
TaiRx, Inc.'s P/E ratio is -6.31. A negative P/E means the company reported a net loss over the last twelve months, so P/E is not a meaningful valuation measure for it right now.
What is 6580.TWO return on equity (ROE)?
TaiRx, Inc.'s return on equity (ROE) is -49.47%. ROE measures net income relative to shareholders' equity. A negative ROE means the company reported a net loss over the period.
What is TaiRx, Inc.'s market cap?
TaiRx, Inc. has a market capitalization of $1.44B.
Does 6580.TWO pay a dividend?
TaiRx, Inc. is not currently showing a dividend yield in our data, which means no recent cash dividend was recorded for it.
How much debt does 6580.TWO carry?
TaiRx, Inc. has a debt-to-equity ratio of 0.01. That compares total borrowings with shareholders' equity: a figure under 1 means equity exceeds debt.
What is 6580.TWO's profit margin?
TaiRx, Inc. reports a net profit margin of 0.00% — the share of revenue left after every cost, including tax and interest.
What sector is 6580.TWO in?
TaiRx, Inc. is classified under Healthcare, in the Biotechnology industry. Ratios are most informative compared with other companies in the same industry rather than across the whole market.
Which exchange is 6580.TWO listed on?
TaiRx, Inc. trades on TWO under the ticker 6580.TWO.
What is 6580.TWO's 52-week range?
Over the last year TaiRx, Inc. has traded between $11.95 and $24.75.
Related Healthcare Stocks
Popular Stocks
Screens 6580.TWO currently matches
On the figures above, TaiRx, Inc. passes the filters for 9 of our ready-made screens, among them Low Debt Stocks, Small Cap Stocks, Debt Free Stocks Under $100. Appearing on a screen means the numbers meet its filters today and nothing more; the list is rebuilt whenever the data changes.
Related stock screens
Data for information only, not investment advice. Figures may be delayed or inaccurate; verify against company filings. See our disclaimer.